What question did this study set out to answer?

To determine if isocitrate dehydrogenase protein levels are prognostic in acute myelogenous leukemia independent of mutation status.

December 8, 2025Blood

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

View Full Paper

Ask AI

Bookmark

Authors

Observational study shows IDH1 and IDH2 levels influence prognosis in acute myelogenous leukemia, highlighting potential treatment strategies.

To determine if isocitrate dehydrogenase protein levels are prognostic in acute myelogenous leukemia independent of mutation status.
Measured levels of 438 proteins using Reverse Phase Protein Arrays in 806 AML samples.
Classified patients into IDH1 and IDH2 tertiles and analyzed for cytogenetic features and outcomes.
Utilized Cox proportional hazards models for uni- and multivariate analyses.
IDH1 levels classified patients into low and high with distinct outcomes, showing low levels correlate with poor prognosis.
IDH2 levels were not prognostic; however, both IDH1 and IDH2 high expression indicated better Overall Survival.
Differential expression analysis revealed potential immune targets like CD4 in low IDH1/2 patients.

Magalhães et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational study shows IDH1 and IDH2 levels influence prognosis in acute myelogenous leukemia, highlighting potential treatment strategies.